ENDRA Life SciencesNDRA +16.05%25 PB Ratio is 3.47 as of Jun. 26, 2026. GuruFocus rates NDRA with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 196 Medical Diagnostics & Research companies, ENDRA Life Sciences ranks worse than 67.35% on this metric.
The historical rank and industry rank for ENDRA Life Sciences's PB Ratio or its related term are showing as below:
NDRA'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 3.58
Current: 3.47
During the past 12 years, ENDRA Life Sciences's highest PB Ratio was 3.58. The lowest was 0.00. And the median was 0.00.
NDRA's PB Ratio is ranked worse than 67.35% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.05
vs NDRA: 3.47
During the past 12 months, ENDRA Life Sciences's average Book Value Per Share Growth Rate was -53.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -91.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -84.70% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of ENDRA Life Sciences was -49.10% per year. The lowest was -92.40% per year. And the median was -91.90% per year.
Back to Basics: PB Ratio
ENDRA Life Sciences (NAS:NDRA) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
ENDRA Life Sciences PB Ratio Related Terms
ENDRA Life Sciences PB Ratio Historical Data
* Premium members only.
The historical data trend for ENDRA Life Sciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, ENDRA Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENDRA Life Sciences PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where ENDRA Life Sciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ENDRA Life Sciences (NDRA) has a PB Ratio of 3.47 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ENDRA Life Sciences and its competitors. According to the industry distribution chart, ENDRA Life Sciences ranks #132 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 67.3%.
Is ENDRA Life Sciences' PB Ratio too high?
ENDRA Life Sciences' current PB Ratio is 3.47. The Medical Diagnostics & Research industry median PB Ratio is 2.05. ENDRA Life Sciences' value of 3.47 is 69.3% above this industry median. Based on the distribution chart, ENDRA Life Sciences ranks #132 out of 196 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, ENDRA Life Sciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does ENDRA Life Sciences' PB Ratio compare to NOTV and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, ENDRA Life Sciences ranks #132 out of 196 companies for PB Ratio. This places ENDRA Life Sciences in the lower half of its industry. The industry median PB Ratio is 2.05. ENDRA Life Sciences' value of 3.47 is 69.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.05, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ENDRA Life Sciences's current PB Ratio of 3.47 is 69.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ENDRA Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ENDRA Life Sciences's current PB Ratio is 3.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENDRA Life Sciences stock overvalued right now?
ENDRA Life Sciences (NDRA) has a current PB Ratio of 3.47. The current PB Ratio is 3.47 and 69.3% above the Medical Diagnostics & Research industry median of 2.05. ENDRA Life Sciences' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For ENDRA Life Sciences (NDRA), the current PB Ratio is 3.47 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
25GF Score
Get the complete analysis for NDRA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NDRA has been successfully added to your 
